In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Drugs Made In America Acquisition Corp. used $244,607 of cash from operations, down 129.3% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
|---|---|---|---|---|---|---|---|
| Operating | |||||||
| Operating cash flow |
-1
|
-0
-129.3%
|
-0
+63.7%
|
-0
|
-0
|
-0
|
-0
|
| Investing | |||||||
| Investing cash flow |
99
|
330
+242.7%
|
—
|
0
|
0
|
-231
|
-231
|
| Financing | |||||||
| Financing cash flow |
-98
|
-98
-92505.0%
|
0
-100.0%
|
0
|
0
|
0
|
231
|
| Ratios | |||||||
| Cash conversion |
-0.08x
|
-0.14x
|
-0.05x
|
-0.59x
|
-0.03x
|
-0.05x
|
-0.20x
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMAA (Nasdaq), DMAAR (Nasdaq), DMAAU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2028614
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Source: SEC EDGAR filings. This is company-reported data, not investment advice.